Mesothelioma Cancer Resources Blog

Amgen, a leading human therapeutics company in the biotechnology industry that  discovers, develops, manufactures, and delivers innovative human therapeutics, has announced that their investigational drug motesanib failed to improve overall survival among patients with non-small cell lung cancer (NSCLC) in a phase III trial.  The company had hoped that the promising drug would offer a …

The American Thoracic Society (ATS) has announced the dates for their annual International Symposium on pulmonary care.  Scheduled for May 13-18, 2011, the conference will be held in Denver, Colorado with the theme “Where today’s science meets tomorrow’s care in pulmonary, critical care and sleep medicine.”  The ATS conference will feature multiple sessions on bioengineering …

Researchers at Cancer Research UK have validated that a simple blood test to “count” the number of circulating tumor cells (CTCs) in a lung cancer patient can predict the patient’s survival.  In addition, the researchers concluded that by identifying CTCs in a lung cancer patient’s bloodstream undergoing treatment, oncologists can monitor the patient’s response and …